48 Wall Street
54 articles with Tyme, Inc.
TYME Announces Abstracts Selected for Presentation at the American Association for Cancer Research, AACR 2020
Preclinical data suggests multiple mechanisms of action for SM-88, including an increase in reactive oxygen species, alterations in autophagy and immunomodulation Preclinical data for TYME-18, an intra-tumoral delivered therapy, displayed statistically significant anti-cancer effects in animal cancer models, including the complete resolution of a majority of tumors Lead pipeline investigational compound, SM-88, represents a new approach designe
Tyme Technologies to Webcast Conference Call of Fourth Quarter and Fiscal Year 2020 Financial and Operating Results on May 20, 2020
Tyme Technologies, Inc. (NASDAQ:TYME) , an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that the Company will host a conference call and live webcast on Wednesday, May 20, 2020 at 5:00 P.M. ET to report its financial and operating results for its fourth quarter and fiscal year ended March 31, 2020. TYME delivered on multiple major milestones in Fiscal Year 2020, including the h
1/20/2020There were plenty of clinical trial announcements this week. Here's a look.
It was another busy week for clinical trials. Here’s a look.
9/16/2019Last week was a busy one for clinical trial results, particularly with the European Committee for Treatment and Research in Multiple Sclerosis 2019 Congress going on. Here’s a look at some of the top clinical trial stories.
TYME CLASS ACTION NOTICE: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Tyme Technologies, Inc. - TYME
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Tyme Technologies, Inc. from March 14, 2018 through January 18, 2019, inclusive.
9/24/2018Here's a look at who's making moves in the biotech and pharma world this week.
Tyme Announces Interim Phase II Safety and Efficacy Data for SM-88 in Prostate Cancer at 2018 ASCO Genitourinary Cancers Symposium
Tyme today announced efficacy and safety data from an ongoing Phase II trial of SM-88 in patients with non-metastatic, biochemical-recurrent prostate cancer.
As part of the deal, Tyme will provide support to Dr. Roach to conduct a randomized, investigator-sponsored trial comparing active surveillance to SM-88 maintenance therapy in patients prior to definitive therapy.
The data was presented at the 2018 ASCO Gastrointestinal Cancers Symposium in San Francisco, Calif. today.
Between November 6 and December 4, 2017, the Company sold approximately 1.2 million shares of Tyme common stock at an average price of $4.05 per share.
Investor conference call scheduled for 10 am ET today.
Tyme Announces Encouraging Efficacy and Safety Data from First Human Study of SM-88 in Women With Metastatic Breast Cancer
No drug-related serious adverse events were observed during SM-88 therapy.
Tyme to Announce Second Quarter Fiscal Year 2017 Operational Update and Schedules Investor Conference Call
The financial results for the quarter ended September 30, 2017 were filed on Form 10-Q with the Securities and Exchange Commission.
Tyme Identifies Potential Method and Biomarker for Converting Malignant Tumors to Inert Calcified Mass
During clinical evaluation of Tyme's lead candidate, it was observed that subsequent to SM-88 therapy some lytic bone lesions converted to benign sclerotic bone.
Tyme's SM-88 Demonstrates Prolonged Overall Survival in Metastatic Cancer Patients Across Multiple Subgroups
The subgroup analysis evaluated three common factors that can influence overall survival in oncology trials.
Tyme Presentation At ESMO Reported 100% Of Current Prostate Cancer Patients Have Demonstrated A Reduction In Circulating Tumor Cells, Most Becoming Undetectable
Tyme’s Updated Long-Term Analysis Shows 29-Month Median Overall Survival In Metastatic Cancer Patients That Achieved Stable Disease